NYSE:TEVA

Teva Pharmaceutical Industries Stock News

Healthcare > Drug Manufacturers - Specialty & Generic

Buy TEVA

*Your capital is at risk

$34.43

-0.0300 (-0.0871%)

At Close: Aug 04, 2026

Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?

10:46am, Monday, 13'th May 2024

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

These 7 Stocks Surged Double-Digits and Have Double-Digits to Go

07:08am, Friday, 10'th May 2024

Earnings reports often catalyze big moves in a stock's price; the bigger the move, the more conviction the market shows. Catalysts for these moves include better-than-expected results, gained traction

TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up

01:15pm, Thursday, 09'th May 2024

TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.

Teva Pharmaceutical Industries (TEVA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

10:36am, Wednesday, 08'th May 2024

Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics co

Teva Pharmaceutical's stock climbs as schizophrenia treatment shows promise

09:15am, Wednesday, 08'th May 2024

Teva Pharmaceutical Industries Ltd.'s American depositary receipts TEVA jumped more than 6% premarket Wednesday after the company reported first-quarter sales that topped expectations and released pos

Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First Quarter

08:53am, Wednesday, 08'th May 2024

Teva stock surged to a five-year high Wednesday after the drugmaker kept its full-year guidance despite missing first-quarter profit views.

Teva Pharm Q1 profit falls short of estimates, revenue gains

07:20am, Wednesday, 08'th May 2024

Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to tre

Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook

07:00am, Wednesday, 08'th May 2024

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2024. Mr. Richard Francis, Teva's President and CEO,

Teva and Medincell's schizophrenia drug meets main goal of late-stage study

06:41am, Wednesday, 08'th May 2024

Teva Pharmaceuticals , and partner Medincell said on Wednesday their experimental schizophrenia drug had met its main goal in a late-stage study.

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

06:30am, Wednesday, 08'th May 2024

PARSIPPANY, N.J. & TEL AVIV & PARIS--(BUSINESS WIRE)--ACCESS HERE THE COMPLETE PRESS RELEASE Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Me

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by